Trial Profile
Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary) ; Aspirin
- Indications Intermittent claudication
- Focus Therapeutic Use
- Acronyms XLPADTRACE
- 01 Feb 2022 Status changed from recruiting to completed.
- 01 Feb 2022 Results assessing the effect of the novel antithrombotic vorapaxar on symptom status in patients with IC, published in the Vascular Medicine.
- 23 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.